Finanztrends
Beste aktive Einschätzung
Deine Einschätzung
Carbylan Therapeutics Inc Aktie
In der Community-Bewertung für Carbylan Therapeutics Inc stehen ausschließlich positive Kriterien im Vordergrund, besonders Lohnenswerte Investition für die nächsten Jahre.
Was spricht für und gegen Carbylan Therapeutics Inc in den nächsten Jahren?
Pro
?
U****************
?
M****
?
M************
Kontra
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
?
A****************
Sag auch du wie 2 andere deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Carbylan Therapeutics Inc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Carbylan Therapeutics Inc | - | - | - | - | - | - | - |
| Pharma Mar S.A. | 0,38 % | -0,93 % | -0,69 % | 0,51 % | 5,71 % | 136,19 % | 7,85 % |
| Clinuvel Pharmaceuticals | -0,37 % | -12,20 % | -14,32 % | -21,17 % | -23,79 % | -49,04 % | -68,11 % |
| Optibiotix Health plc | -0,78 % | 3,20 % | -10,42 % | -35,50 % | -14,00 % | -84,27 % | -88,06 % |
Kommentare
News
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals (NASDAQ:KALV), reported the exercise of 33,800 options into common stock and the immediate sale of those shares for a total
DRI Healthcare Trust Q1 Earnings Call Highlights
DRI Healthcare Trust (TSE:DHT.UN) reported higher first-quarter income and expanded margins as management said the royalty investment company continued to benefit from its post-internalization cost
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
KalVista Pharmaceuticals (NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy’s Chiesi Group will